During the last session, Cue Biopharma Inc (NASDAQ:CUE)’s traded shares were 0.46 million, with the beta value of the company hitting 1.42. At the end of the trading day, the stock’s price was $0.66, reflecting an intraday gain of 13.00% or $0.08. The 52-week high for the CUE share is $1.99, that puts it down -201.52 from that peak though still a striking 31.82% gain since the share price plummeted to a 52-week low of $0.45. The company’s market capitalization is $49.39M, and the average intraday trading volume over the past 10 days was 0.17 million shares, and the average trade volume was 163.70K shares over the past three months.
Cue Biopharma Inc (CUE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CUE has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.13.
Cue Biopharma Inc (NASDAQ:CUE) trade information
Cue Biopharma Inc (CUE) registered a 13.00% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 13.00% in intraday trading to $0.66, hitting a weekly high. The stock’s 5-day price performance is 2.58%, and it has moved by -7.34% in 30 days. Based on these gigs, the overall price performance for the year is -51.80%. The short interest in Cue Biopharma Inc (NASDAQ:CUE) is 0.77 million shares and it means that shorts have 4.93 day(s) to cover.
The consensus price target of analysts on Wall Street is $4, which implies an increase of 83.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $7 respectively. As a result, CUE is trading at a discount of -960.61% off the target high and -203.03% off the low.
Cue Biopharma Inc (CUE) estimates and forecasts
In the rating firms’ projections, revenue will decrease -31.09% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2M as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 2M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.66M and 3.34M respectively. In this case, analysts expect current quarter sales to shrink by -24.76% and then drop by -40.05% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 15.39%. While earnings are projected to return 18.06% in 2025, the next five years will return 12.04% per annum.
CUE Dividends
Cue Biopharma Inc is due to release its next quarterly earnings on 2025-May-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Cue Biopharma Inc (NASDAQ:CUE)’s Major holders
Cue Biopharma Inc insiders own 0.35% of total outstanding shares while institutional holders control 15.19%, with the float percentage being 15.24%. BLEICHROEDER LP is the largest shareholder of the company, while 64.0 institutions own stock in it. As of 2024-06-30, the company held over 2.86 million shares (or 5.7849% of all shares), a total value of $3.55 million in shares.
The next largest institutional holding, with 2.4 million shares, is of SLATE PATH CAPITAL LP’s that is approximately 4.8567% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.98 million.
